• Molecular NameLevamisole
  • Synonymdl-Tetramisol; dl-Tetramisole; L-Tetramisole; Levamisol [INN-Spanish]; Levamisole hydrochloride; Levamisolum [INN-Latin]; Phenyl imidothiazole
  • Weight204.297
  • Drugbank_IDDB00848
  • ACS_NO14769-73-4
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.15
  • pka8.0
  • LogD (pH=7, predicted)1.11
  • Solubility (experiment)210 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.97
  • LogSw (predicted, AB/LogsW2.0)0.08
  • Sw (mg/ml) (predicted, ACD/Labs)0.31
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds1
  • TPSA40.9
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antibiotic belonging to a class of synthetic imidazothiazole derivatives.
  • Absorption_value95.0
  • Absorption (description)Levamisole is readily absorbed after oral administration
  • Caco_2N/A
  • Bioavailability65.0
  • Protein binding22.5
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmExtensively metabolised.
  • Half life4 h
  • ExcretionIt is almost completely excreted in the urine and faeces within 48 h.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)LD50=180 mg/kg
  • LD50 (mouse)N/A